Drugs / Daidzein
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT07623044 | May → Jul 2026 overdue | metabolic dysfunction-associated steatotic liver disease | Eastern Hepatobiliary Surgery Hospital | Not yet recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01497977 | Sep 2008 → Jun 2010 | hypolipoproteinemia | American Medical Academy, Serbia | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Daidzein | “The red clover capsule consisted of 4 isoflavones: biokain A (23mg), daidzein (1mg), formononetin (15mg) and genistein (1mg).” NCT01497977 ↗ |
| Known as | 4',7-dihydroxyisoflavone | ChEMBL registry synonym — accepted as the source's own label CHEMBL8145 ↗ |
| Modality | Small molecule | — CHEMBL8145 ↗ |
| Route | Oral | “Daidzein will be administered orally as capsules.” NCT07623044 ↗ |